Log in

XINT Xintela AB OMXSTO · Sweden

Xintela AB (XINT) news

Xintela AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker XINT, recorded under Sweden. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Xintela AB news

We have not published a story on Xintela AB yet. When there is news, it will appear here.

Questions about Xintela AB

What is the ticker symbol of Xintela AB?

Xintela AB trades under the ticker XINT on OMXSTO.

Where is Xintela AB listed?

Xintela AB is listed on OMXSTO.

Which country or territory is Xintela AB listed under?

Our directory records Xintela AB under Sweden.

What does Xintela AB do?

Our directory classifies Xintela AB as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Xintela AB?

The ISIN recorded for Xintela AB is SE0007756903.

Does aibio.space cover Xintela AB?

aibio.space lists Xintela AB among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Xintela AB?

Companies in our directory listed in the same country and business area as Xintela AB: Biovica International AB, Fluicell AB, PILA PHARMA AB, Intervacc AB, Mendus AB, NATTARO LABS AB.

Investor discussion: Xintela AB

Members talk about Xintela AB (XINT). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OMXSTO:XINT on TradingView.

Listing details

Xintela AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker XINT, recorded under Sweden. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Xintela AB
Ticker
XINT
Listing
OMXSTO
Country or territory
Sweden
Business scope
Biotechnology
ISIN
SE0007756903
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.